Clinical features of recurrent stroke after intracerebral hemorrhage.

There have been many reports about the prognosis and risk factors of stroke recurrence following brain infarction (BI). However, little is known about the stroke recurrence after primary intracerebral hemorrhage (PICH). Therefore, we explored the recurrent stroke patients after initial PICH retrospectively, to reveal the critical factors of stroke recurrence.

Clinical evaluation of lacunar infarction and branch atheromatous disease.

Patients with branch atheromatous disease (BAD) are more likely to experience neurologic deficits compared with those with lacunar infarction (LI), although both disorders are forms of intracranial deep brain infarction. We clinically evaluated patients with BAD (n = 42) and LI (n = 57) to investigate why patients with BAD tend to experience progressing stroke. Patients presenting to our hospital with acute ischemic stroke between April 2008 and March 2009 were screened.

[Remote cerebellar hemorrhage after single burr hole drainage of chronic subdural hematoma of the elderly].

Remote cerebellar hemorrhage is a usual complication after supratentorial craniotomy. Especially, only several cases have been reported regarding the occurrence of remote cerebellar hemorrhage after burr hole drainage for the treatment of chronic subdural hematoma (CSDH). In this paper, we present an elder patient with this rare postoperative complication.

Free radical scavenger, edaravone, reduces the lesion size of lacunar infarction in human brain ischemic stroke.

Background: Although free radicals have been reported to play a role in the expansion of ischemic brain lesions, the effect of free radical scavengers is still under debate. In this study, the temporal profile of ischemic stroke lesion sizes was assessed for more than one year to evaluate the effect of edaravone which might reduce ischemic damage.

Methods: We sequentially enrolled acute ischemic stroke patients, who admitted between April 2003 and March 2004, into the edaravone(-) group (n = 83) and, who admitted between April 2004 and March 2005, into the edaravone(+) group (n = 93).